Drug intelligence / Profile preview

MK-0472

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-0472 is an investigational small molecule inhibitor of Src homology phosphotyrosyl phosphatase 2 (SHP2, also known as PTPN11), being developed by Merck Sharp & Dohme for the treatment of advanced or metastatic solid tumors. SHP2 is a protein tyrosine phosphatase involved in cell signaling pathways that regulate cell growth and survival, and its inhibition may disrupt oncogenic signaling in cancer cells. MK-0472 is currently being evaluated as monotherapy and in combination with pembrolizumab (a PD-1 inhibitor) or MK-1084 in phase 1 clinical trials for patients with histologically or cytologically confirmed advanced/metastatic solid tumors[1][4][5][7].

Other names: SHP2 inhibitorSHP-2 inhibitorSHP 2 inhibitorMSD and Taiho-SHP2-small molecule-Oncology

Targets

PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)

Beyond the preview

Go deeper on MK-0472.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-0472.

Explore the full profile